Lupus Foundation of America Statement on Results for Clinical Study
of CellCept Released by Aspreva Pharmaceutical Company
Statement by Sandra C. Raymond, President & CEO of the LupusFoundation of America, Inc. WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The LupusFoundation of America, Inc. and more than 1.5 million Americanswith lupus have been awaiting the preliminary findings of the PhaseIII clinical trials for CellCept(R), a potential treatment forlupus kidney disease being tested by
Aspreva...
Aspreva and Roche Announce Preliminary Results for Phase III Study
Evaluating CellCept in Lupus Nephritis
VICTORIA, BC, Canada and BASEL, Switzerland, June 27 /CNW/ -
Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) andRoche today released preliminary results for a clinical trialcomparing CellCept (oral mycophenolate mofetil, MMF) to intravenouscyclophosphamide (IVC), which is the current standard of care, forinducing treatment response in the induction phase of patientssuffering fro...